Clinical Trials Using EGFRBi-Armed Autologous T Cells

Clinical trials are research studies that involve people. The clinical trials on this list are studying EGFRBi-Armed Autologous T Cells. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • EGFR Bispecific Antibody Armed T cells in Combination with Radiation Therapy and Temozolomide in Treating Participants with Newly Diagnosed Glioblastoma

    This phase I trial studies the side effects and best dose of EGFR bi-armed autologous T cells in combination with radiation therapy and temozolomide in treating participants with newly diagnosed glioblastoma. EGFR bi-armed autologous T cells target the EGFR molecules on glioblastoma tumor cells and use the body's own immune system to destroy those tumor cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving EGFR bi-armed autologous T cells with radiation therapy and temozolomide may work better in treating participants with newly diagnosed glioblastoma.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • EGFRBi-Armed Autologous T Cells in Treating Patients with Recurrent or Refractory Glioblastoma

    This phase I / II trial studies the side effects and best dose of epidermal growth factor receptor bispecific antibody (EGFRBi)-armed autologous T cells and how well it works in treating patients with glioblastoma that have come back or does not respond to treatment. EGFRBi-armed autologous T cells coated with antibodies (proteins used by the immune system to target and kill foreign objects such as cancer cells) may have great ability to seek out, attach to, and destroy glioblastoma cells.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan